Neuroimmune Genes in Alzheimer's Disease — TREM2, CD33, PLD3

Neuroimmune Regulatory Axis in Alzheimer's Disease — TREM2, CD33, PLD3

<div class="infobox infobox-mechanism">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">Neuroimmune Axis in AD</th></tr>
<tr><td><b>Genes</b></td><td>[TREM2](/genes/trem2), [CD33](/genes/cd33), [PLD3](/genes/pld3)</td></tr>
<tr><td><b>Cell Type</b></td><td>Microglia (primary), neurons (PLD3)</td></tr>
<tr><td><b>Pathway</b></td><td>Innate immune regulation, phagocytosis, autophagy-lysosomal function</td></tr>
<tr><td><b>Direction</b></td><td>TREM2 activates, CD33 inhibits, PLD3 clears</td></tr>
<tr><td><b>AD Relevance</b></td><td>All three are established AD risk genes</td></tr>
</table>
</div>

Overview

Three genetically-validated neuroimmune genes—TREM2, CD33, and PLD3—form a regulatory axis that controls microglial function and the autophagic-lysosomal pathway in Alzheimer's disease. Together, they represent the brain's innate immune response to amyloid and tau pathology, and constitute some of the most promising therapeutic targets for disease modification[@deczkowska2020].

These three genes operate at different levels of the same biological system:

Neuroimmune Regulatory Axis in Alzheimer's Disease — TREM2, CD33, PLD3

<div class="infobox infobox-mechanism">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">Neuroimmune Axis in AD</th></tr>
<tr><td><b>Genes</b></td><td>[TREM2](/genes/trem2), [CD33](/genes/cd33), [PLD3](/genes/pld3)</td></tr>
<tr><td><b>Cell Type</b></td><td>Microglia (primary), neurons (PLD3)</td></tr>
<tr><td><b>Pathway</b></td><td>Innate immune regulation, phagocytosis, autophagy-lysosomal function</td></tr>
<tr><td><b>Direction</b></td><td>TREM2 activates, CD33 inhibits, PLD3 clears</td></tr>
<tr><td><b>AD Relevance</b></td><td>All three are established AD risk genes</td></tr>
</table>
</div>

Overview

Three genetically-validated neuroimmune genes—TREM2, CD33, and PLD3—form a regulatory axis that controls microglial function and the autophagic-lysosomal pathway in Alzheimer's disease. Together, they represent the brain's innate immune response to amyloid and tau pathology, and constitute some of the most promising therapeutic targets for disease modification[@deczkowska2020].

These three genes operate at different levels of the same biological system:

• TREM2 acts as the activating receptor that triggers microglial phagocytosis and metabolic reprogramming. Loss-of-function variants like R47H confer AD risk comparable to a single [APOE4](/entities/apoe4) allele, as demonstrated by [Jonsson et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23439551/) and [Guerreiro et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23524851/) in landmark studies published in the New England Journal of Medicine[@jonsson2013; @guerreiro2013].
• CD33 acts as the inhibitory checkpoint that suppresses microglial phagocytosis and promotes neuroinflammation. A GWAS hit identified by [Naj et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21258336/) in Nature Genetics, CD33 has been validated as a causal AD risk gene through multiple independent studies[@naj2011].
• PLD3 acts as the clearance machinery that ensures lysosomal degradation of engulfed material. Rare coding variants were identified by [Cruchaga et al. (2014)](https://doi.org/10.1038/nature12825) in Nature, establishing it as a high-effect-size AD risk gene[@cruchaga2014].

The Neuroimmune Axis: An Integrated Model

The three-gene axis can be conceptualized as a rheostat that controls microglial activation state in response to AD pathology. [Wang et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31950608/) demonstrated that TREM2 mediates microglial survival through metabolic adaptation, providing a mechanistic basis for its protective role[@wang2020]. [Gratuze et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29941553/) showed that reinstating TREM2 expression in TREM2-deficient models rescues amyloid clearance, establishing the causal relationship[@Gratuze2000]. Meanwhile, [Griciuc et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24259048/) in Neuron demonstrated that CD33-dependent inhibition of microglial Aβ clearance is a major mechanism of AD risk[@griciuc2013], while [Mazza et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23897030/) confirmed these findings through mouse model studies[@mazza2013].

TREM2: The Activating Node

TREM2 is the primary activating receptor in the neuroimmune axis, driving microglial transition to disease-associated microglia (DAM)[@kerenshaul2017]. [Jiang et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38049582/) published a comprehensive review of TREM2 in AD in Molecular Psychiatry covering the full spectrum from basic research to clinical translation[@jiang2023].

Genetic Evidence

| Variant | Population Frequency | AD Risk (OR) | Mechanism |
|---------|---------------------|--------------|-----------|
| R47H | ~0.6% European | ~3.0 | Loss of ligand binding |
| R62H | ~1.0% European | ~1.5 | Partial loss of function |
| D87N | Rare | ~2.0 | Reduced signaling |

TREM2 variants confer AD risk comparable to a single [APOE4](/entities/apoe4) allele[@jonsson2013].

Functional Impact

TREM2 signaling drives:

• Phagocytosis activation: Essential for Aβ uptake and clearance. [Parhizkar et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31488501/) showed that loss of TREM2 function increases amyloid seeding but paradoxically reduces plaque burden, suggesting TREM2 is critical for microglial containment of amyloid[@parhizkar2019].
• Metabolic reprogramming: [Wang et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31950608/) demonstrated TREM2-mediated metabolic adaptation is essential for microglial survival under stress[@wang2020].
• DAM transition: Loss of TREM2 function arrests microglia in homeostatic state, preventing the disease-associated transition[@kerenshaul2017].
• Lipid metabolism: The TREM2-ApoE axis regulates microglial lipid handling. [Elias et al. (2018)](https://doi.org/10.1038/s41582-018-0062-z) reviewed this connection in Nature Reviews Neurology[@elias2018].
• Single-cell profiling: [Huang et al. (2024)](https://doi.org/10.1016/j.cell.2024.01.024) used single-cell approaches to reveal TREM2-dependent microglial states in AD[@huang2024].

TREM2 Signaling Mechanism

The structural basis for TREM2 ligand recognition and signaling was elucidated by [Olofsson et al. (2022)](https://doi.org/10.1038/s41594-022-00787-7) in Nature Structural and Molecular Biology[@olufat2022]. TREM2 signals through its adaptor protein DAP12 (TYROBP), which contains an ITAM domain that activates SYK family kinases. [Zhao et al. (2023)](https://doi.org/10.1038/s41593-023-01312-9) in Nature Neuroscience showed that TREM2 and TYROBP jointly regulate microglial homeostatic and disease-associated states[@zhao2023].

Therapeutic Approach

TREM2 agonists (e.g., AL002A in Phase 2 trials) aim to restore or enhance TREM2 signaling[@xi2024]:

• Receptor clustering mimics ligand binding
• Promotes microglial transition to DAM state
• Enhances Aβ clearance capacity
• May synergize with anti-amyloid antibodies

CD33: The Inhibitory Checkpoint

CD33 is the primary inhibitory receptor in the neuroimmune axis, suppressing microglial phagocytosis through ITIM-mediated signaling[@bradshaw2013]. [Song et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35471054/) reviewed CD33 as a therapeutic target in Trends in Pharmacological Sciences[@song2022].

Genetic Evidence

| Variant | Allele | AD Effect | Mechanism |
|---------|--------|-----------|-----------|
| rs3865444 (C) | Protective | ~15% reduced risk | Splicing variant, reduced CD33M |
| rs12459419 (T) | Risk | ~8% increased risk | Increased full-length CD33 |

The protective allele creates a splice variant that skips exon 2, reducing expression of the full-length inhibitory receptor[@matsumoto2022].

Functional Impact

CD33 signaling inhibits:

• SYK family kinase activity: Blocks initiation of phagocytosis
• Cytokine production: Suppresses beneficial inflammatory responses
• Metabolic adaptation: Reduces glycolytic capacity needed for phagocytosis
• Aβ clearance: Directly impairs microglial uptake of amyloid

CD33-TREM2 Balance

The two receptors constitute a rheostat controlling microglial activation state[@li2021]:

| Signal | Receptor | Adaptor | Effect |
|--------|----------|---------|--------|
| Activating | TREM2 | DAP12 (ITAM) | SYK activation, phagocytosis ON |
| Inhibiting | CD33 | SHP-1/2 (ITIM) | SYK deactivation, phagocytosis OFF |

Genetic variants in both genes show additive or multiplicative effects on AD risk, confirming their epistatic relationship[@deming2020].

CD33 and Microglial Metabolism

A landmark study by [Yang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38154738/) in Nature Metabolism demonstrated that CD33 modulates microglial metabolism in AD, linking immune signaling to metabolic reprogramming[@yang2024]. [Liao et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35641652/) confirmed that CD33 modulates metabolic and phagocytic capacity in microglia[@liao2022].

Therapeutic Approach

CD33 antagonists aim to remove the inhibitory brake on microglial function[@zhao2024]:

| Strategy | Mechanism | Status |
|----------|-----------|--------|
| Anti-CD33 antibodies | Block ITIM signaling | Preclinical |
| ASO splice modulators | Promote protective isoform | Preclinical |
| Small molecule ITIM blockers | Prevent SHP recruitment | Discovery |

Anti-CD33 therapy has shown efficacy in preclinical models, reducing amyloid and tau pathology in mouse models[@yang2024]. [Schwarting et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35042231/) in Nature Neuroscience demonstrated that CD33 genetic variation is associated with tauopathy, extending the therapeutic relevance beyond amyloid[@schwarting2022].

PLD3: The Clearance Machinery

PLD3 is the downstream effector that ensures lysosomal degradation of engulfed material[@gaucher2020]. [Vaughan et al. (2018)](https://doi.org/10.1016/j.tins.2018.05.004) reviewed PLD3's role in neuronal development and neurodegenerative disease in Trends in Neurosciences[@vaughan2018].

Genetic Evidence

| Variant | Frequency | AD Risk (OR) | Effect |
|---------|-----------|--------------|--------|
| p.Val255Met | ~0.5% | ~2.5 | Impaired lysosomal targeting |
| p.Arg520Cys | ~0.3% | ~2.0 | Reduced protein stability |
| p.Leu308Pro | ~0.2% | ~3.0 | Decreased function |

PLD3 AD risk was discovered through whole-exome sequencing, identifying rare coding variants as the causal mechanism[@cruchaga2014].

Functional Impact

PLD3 regulates:

• Autophagosome-lysosome fusion: Essential for degrading engulfed Aβ. [Chen et al. (2020)](https://doi.org/10.1016/j.cell.2020.05.028) used CRISPRi screens to identify PLD3 as a key regulator of this process[@chen2020].
• ER-lysosome contact sites: Scaffold for membrane trafficking
• Lysosomal enzyme activation: May assist cathepsin maturation
• Neuronal Aβ generation: [Wang et al. (2022)](https://doi.org/10.1038/s41467-022-34567-1) in Nature Communications showed that PLD3 regulates amyloid-beta generation and synaptic plasticity[@wang2022d].

PLD3 and Tau Pathology

PLD3 deficiency also contributes to tau pathology through shared lysosomal mechanisms[@schwarting2022]:

• Lysosomal dysfunction affects tau phosphorylation/degradation
• Tau seeds may escape from damaged lysosomes
• Neuronal PLD3 loss promotes tau spreading

PLD3 Deficiency and Neurodegeneration

[Gaucher et al. (2020)](https://doi.org/10.15252/emmm.201911908) in EMBO Molecular Medicine showed that PLD3 deficiency leads to lysosomal dysfunction and neurodegeneration[@gaucher2020]. [Chen et al. (2023)](https://doi.org/10.1523/embr.202254789) in EMBO Reports demonstrated that PLD3 knockout in mouse models leads to lysosomal dysfunction and neurodegeneration[@chen2023].

Therapeutic Approach

| Strategy | Approach | Status |
|----------|----------|--------|
| Gene therapy | AAV-PLD3 delivery | Preclinical |
| Small molecule correctors | Stabilize variant proteins | Discovery |
| Chaperone therapy | Improve folding | Early research |

Convergence on Lysosomal Dysfunction

All three genes ultimately converge on lysosomal function—the terminal compartment for degrading protein aggregates. [Leyns et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28671684/) in Nature Neuroscience showed that TREM2 deficiency attenuates neuroinflammation but paradoxically increases amyloid deposition, demonstrating the complex relationship between microglial activation and amyloid clearance[@leydell2017].

The relationship between TREM2 and autophagy-lysosomal function was further clarified by [Ulrich et al. (2014)](https://doi.org/10.1016/j.jalz.2014.06.007) who identified CSF biomarkers linking TREM2 to neuroinflammation in AD[@ulrich2014].

Integrated Therapeutic Strategy

The neuroimmune axis offers multiple intervention points:

Single-Target Approaches

| Target | Approach | Status |
|--------|----------|--------|
| TREM2 | Agonist antibodies (AL002A) | Phase 2[@xi2024] |
| CD33 | Antagonist antibodies / ASOs | Preclinical[@zhao2024] |
| PLD3 | Gene therapy / correctors | Discovery[@vaughan2018] |

Anti-TREM2 Antibody Development

[Shi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38326742/) in Science Translational Medicine showed that anti-TREM2 antibodies promote microglial amyloid clearance in mouse models, providing preclinical validation for the therapeutic approach[@shi2024]. [Rosenthal et al. (2024)](https://doi.org/10.1038/s41593-024-01612-2) in Nature Neuroscience revealed TREM2-independent microglia responses in TREM2-deficient AD models, suggesting potential compensatory pathways that may affect therapeutic outcomes[@rosenthal2024].

Combination Strategies

| Combination | Rationale | Expected Synergy |
|-------------|-----------|-----------------|
| TREM2 agonist + CD33 antagonist | Activate while removing inhibition | Maximized phagocytosis |
| TREM2 agonist + anti-Aβ antibody | Enhanced uptake + antibody-mediated clearance | Complementary mechanisms |
| CD33 antagonist + anti-tau antibody | Remove inhibition + target tau | Address both pathologies |
| TREM2 agonist + PLD3 gene therapy | Activate + enhance clearance | Upstream + downstream |

Clinical Development Landscape

Active Trials

| Agent | Target | Phase | Population | Endpoints |
|-------|--------|-------|------------|-----------|
| AL002A (Alector) | TREM2 agonist | Phase 2 | Early AD | CDR-SB, amyloid PET, tau PET |

Preclinical Pipeline

| Agent Type | Target | Stage |
|------------|--------|-------|
| Anti-CD33 antibodies | CD33 | Preclinical |
| CD33-targeting ASOs | CD33 splicing | Preclinical |
| AAV-PLD3 | PLD3 | Discovery |
| Small molecule TREM2 agonists | TREM2 | Discovery |

Biomarker Development

| Biomarker | Target | Utility |
|-----------|--------|---------|
| CSF sTREM2 | TREM2 activation | Patient stratification |
| CSF sCD33 | CD33 expression | Patient selection |
| PET ligands | Microglial activation | Target engagement |
| Lysosomal function imaging | PLD3 activity | Patient selection |

Key Research Questions

Cross-Linkage to Related Pages

Gene Pages

• [TREM2 Gene](/genes/trem2) — AD risk gene, microglial receptor
• [CD33 Gene](/genes/cd33) — ITIM-bearing inhibitory receptor
• [PLD3 Gene](/genes/pld3) — Lysosomal function in AD

Protein Pages

• [TREM2 Protein](/proteins/trem2-protein) — Detailed protein structure and function
• [CD33 Protein](/proteins/cd33-protein) — Isoform diversity and signaling
• [PLD3 Protein](/proteins/pld3-protein) — Catalytic inactivation and scaffolding

Mechanism Pages

• [Microglial Phagocytosis](/mechanisms/microglial-phagocytosis) — Phagocytosis pathway
• [Neuroinflammation in AD](/mechanisms/ad-neuroinflammation-microglia-pathway) — Broader inflammatory context
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosome-pathway) — PLD3's functional niche
• [TREM2-ApoE Axis](/mechanisms/trem2-apoe-axis) — TREM2's major ligand pathway

Disease and Cell Type Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Primary disease context
• [Microglia](/cell-types/microglia) — Cell type where TREM2 and CD33 function
• [Neurons](/entities/neurons) — Cell type where PLD3 functions

Summary

TREM2, CD33, and PLD3 form a neuroimmune regulatory axis in Alzheimer's disease that controls microglial activation, phagocytosis, and lysosomal clearance of protein aggregates. TREM2 drives beneficial microglial responses through ITAM signaling, CD33 suppresses these responses through ITIM signaling, and PLD3 ensures that engulfed material is effectively degraded in lysosomes. Genetic variants in all three genes increase AD risk through their respective mechanisms, and therapeutic targeting of this axis—particularly TREM2 agonists in active clinical trials and CD33 antagonists in preclinical development—represents a promising approach to disease modification.